Robert A. Lenz - Feb 14, 2024 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
Head of R&D
Signature
/s/ Joshua Pinto, as Attorney-in-Fact for Robert A. Lenz
Stock symbol
NMRA
Transactions as of
Feb 14, 2024
Transactions value $
$0
Form type
4
Date filed
2/16/2024, 04:13 PM
Previous filing
Sep 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NMRA Common Stock Award $0 +50K +14.17% $0.00 403K Feb 14, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NMRA Stock Option (Right to Buy) Award $0 +100K $0.00 100K Feb 14, 2024 Common Stock 100K $18.07 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.
F2 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.